
    
      The objective of this continued follow-up of ILLUMENATE Pivotal Study subjects is to
      demonstrate the long term safety and effectiveness of the Stellarex DCB.

      Each enrolled subject will be followed for 5 years (60 months) after treatment. A follow-up
      office visit will occur at 24 and 36 months. A follow-up telephone contact or an optional
      office visit will occur at 48 and 60 months.
    
  